Eagle Restructured its Licensing Agreement with Teva for Bendeka (bendamustine hydrochloride)

 Eagle Restructured its Licensing Agreement with Teva for Bendeka (bendamustine hydrochloride)

Eagle Restructured its Licensing Agreement with Teva for Bendeka (bendamustine hydrochloride)

Shots:

  • Eagle to receive royalties increased from 25% to 30% on sales of Bendeka in the US and will keep increasing by 1% until it reaches 32%, on every Oct 1,2019. The US royalty term is set to expire in 2033 from 2025
  • Additionally, the restructuring includes Eagle to manufacture Bemdeka for the US market and has agreed to contribute a portion of litigation expense. In 2015, Eagle and Teva enter into a license agreement to commercialize Bendeka (formely Treanda) for CLL and NHL
  • Bendeka (bendamustine hydrochloride) a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation has been approved by FDA for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) and has also received Orphan drug Designation from FDA 

Click here to read full press release/ article | Ref: BusinessWire | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post